Drug Discovery@nature.com 1 February 2013

TABLE OF CONTENTS 1 February 2013 News Analysis Research Highlights Research & Reviews Careers Nature Reviews Drug Discovery is on Twitter Advertisement We've got something to show you...! SEARCH - EXPLORE - DISCOVER - IDENTIFY Tap in to find out more   News Top 2012 FDA drug approvals doi:10.1038/nrd3946 FDA drug approval bonanza sees cancer and orphan drugs on top again. Full Text Target watch: Drugging the epigenome doi:10.1038/nrd3943 This article presents a data-mining approach to explore the drug target landscape for epigenetics. Full Text An Audience With: Mike Yeadon doi:10.1038/nrd3936 Pfizer’s former head of allergy and respiratory biology Mike Yeadon discusses his own start-up, Ziarco, which has licensed several former Pfizer compounds and secured UK£16.8 million in venture funding. Full Text Work resumes on lethal flu strains doi:10.1038/493460a Study of lab-made viruses a ‘public-health responsibility’. Full Text Analysis Top In silico drug design doi:10.1038/scibx.2013.50 A Dundee-UNC team has created a computational algorithm that mines medicinal chemistry literature to predict new ligands that bind specific combinations of GPCRs. Full Text Smoking cessation drugs market doi:10.1038/nrd3914 This analysis looks at smoking cessation therapies currently in development, including the novel approach of vaccinating smokers against nicotine. Full Text Research Highlights Top Antibacterial drugs: New antibiotics on the horizon? doi:10.1038/nrd3940 Two recent papers report novel strategies for combating the prevalent bacterial pathogen Staphylococcus aureus. Full Text Neurodegenerative disease: Targeting pre-existing plaques in AD doi:10.1038/nrd3939 Researchers have developed a plaque-specific monoclonal antibody that can clear existing plaques without the side effects seen with other anti-amyloid-β therapeutics in development. Full Text Anticancer drugs: Assault on MALT1 doi:10.1038/nrd3942 Two new studies have identified small-molecule inhibitors of MALT1 that show anticancer activity in vitro and in vivo. Full Text Research & Reviews Top Targeting eosinophils in allergy, inflammation and beyond doi:10.1038/nrd3838 The authors describe recent advances in the development of the first generation of therapies that target eosinophils, as well as emerging strategies. Full Text Advances in targeting cell surface signalling molecules for immune modulation doi:10.1038/nrd3877 This review discusses immunomodulatory signalling pathways that provide targets for therapeutic intervention and the current state of drug development in the field. Full Text Potentiating antibacterial activity by predictably enhancing endogenous microbial ROS production doi:10.1038/nbt.2458 Researchers present a systems-based method to tune ROS production in bacteria and demonstrate that increased microbial ROS production can potentiate killing by oxidants and antibiotics. Full Text Ablation of TRIP-Br2, a regulator of fat lipolysis, thermogenesis and oxidative metabolism, prevents diet-induced obesity and insulin resistance doi:10.1038/nm.3056 As expression of this transcriptional regulator is elevated in fat from obese humans, TRIP-Br2 might be a new therapeutic target against insulin resistance and hyperlipidemia. Full Text Drug Discovery JOBS of the week Postdoc Research Trainee - Movement Disorders University of Tennessee Health Science Center Analytical Chemist (GC-MS) Hudson Shribman Scientific Recruitment Ltd Junior Research Fellow in Lymphoma Biology IOR - Institute of Oncology Research Post-doctoral researcher - structure-based drug design Structural Biology Brussels (Vrije Universiteit Brussel / VIB) Ph.D. Level Research Investigators The Genomics Institute of the Novartis Research Foundation (GNF) More Science jobs from Drug Discovery EVENT Tumor Imaging in Cancer Drug Development 04.30.13 Boston, US More science events from Careers Top Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text Top Advertisement SciBX: Science-Business eXchange is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Recommend SciBX to your library today.   Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.